Indicazioni all'uso della diidroergotamina nel trattamento del dolore emicranico alla luce della informativa AIFA 2013

Translated title of the contribution: Indications for use of dihydroergotamine in the treatment of migraine pain in the light of the 2013 AIFA recommendations

Luisa Gervasio, Cinzia Fattore, Ennio Pucci, Fabio Antonaci

Research output: Contribution to journalReview articlepeer-review

Abstract

In the light of the 2009 italian law on service pharmacies, more and more pharmacies are participating in the process of ensuring healthcare quality and safety. Traditional pharmacies are tending to become places involved in the production and promotion of health and are becoming a valuable means of communication between citizens and healthcare operators, with a view to improving quality of life and promoting the common good. All this requires pharmacists to collaborate synergistically with different health professionals, mainly specialists and hospital doctors, nurses and general practitioners; this approach, which requires expertise and innovation, will lead to the definition of diagnostic/treatment pathways that increasingly meet citizens' needs.

Translated title of the contributionIndications for use of dihydroergotamine in the treatment of migraine pain in the light of the 2013 AIFA recommendations
Original languageItalian
Pages (from-to)68-72
Number of pages5
JournalConfinia Cephalalgica
Volume26
Issue number2
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Indications for use of dihydroergotamine in the treatment of migraine pain in the light of the 2013 AIFA recommendations'. Together they form a unique fingerprint.

Cite this